They showed that itaconate downregulates the gene expression of peroxisome proliferator-activated receptor gamma (PPARγ), a colorectal cancer suppressor, in M2-like macrophages and upregulates anti-inflammatory cytokines, suggesting that it is associated with worse clinical outcomes in colorectal cancer patients [19]. Here, PPARG is linked to colorectal cancer.